On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

PCI significantly expands Global Clinical Services business through Biotec acquisition

Philadelphia, PA – September 19, 2014 - PCI is pleased to announce it has acquired Biotec Services International (Biotec). Biotec is a leading provider of Clinical Trial Services and...


Company reinforces its commitment to global public health with more investment in antibiotic R&D than any company worldwide Lexington, Massachusetts, U.S. and Zurich, Switzerland, September 18,...

Calithera tees up $84M IPO; Allozyne scrapped for parts;

@FierceBiotech: Cubist makes Euro landfall with a $400M purse for antibiotics R&D. More | Follow @FierceBiotech @JohnCFierce: FYI, I'm setting up some meets after the executive panel in...

Frazier Healthcare Appoints David Socks as Venture Partner, Establishes Boston Presence

MENLO PARK, Calif.--Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announced today that David Socks has joined the Frazier Life Sciences...

French immuno-oncology biotech OSE eyes an EU IPO

The U.S. boom in biotech IPOs has largely failed to drift across the Atlantic and galvanize many floats in Europe, but France's OSE Pharma is looking to buck that trend in hopes of bankrolling late-stage studies for its immuno-oncology candidate.

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Antibiotics R&D to get critical lift by executive order, Obama advisory group

Antibiotics development is about to get a much-need boost with the release of new federal proposals aimed at curbing rising antimicrobial resistance infections caused by so-called superbugs.

Merck KGaA (MKGAF.PK) Strengthens Executive Board

DARMSTADT, Germany, Sept. 18, 2014 /CNW/ - Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive...

Epizyme Appoints Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D., as Vice President, Business Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers,...